Novel aspartame derivative crystal and process for producing the same
CA 2331819 A1 · Owner: Nagai, Takeshi · Inventors: Kishishita, Akihiro; Ishida, Hirotoshi; Nagai, Takeshi
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A methyl ester of N-N-(3,3-dimethylbutyl)-L-.alpha.-aspartyl-L-phenylalanine (A-form crystals) having characteristic X-ray diffraction peaks e.g. at , diffraction angles of at least 6.0~ 24.8~, 8.2~, and 16.5~ (2.theta. CuK.alpha. line) is dried to a water content below 3 wt.%. The thus-dried crystals are novel crystals (C-form crystals) of the methyl ester of N-N-(3,3dimethylbutyl)-L-.alpha.-aspartyl-L-phenylalanine which have an excellent rate of dissolution. These crystals, when examined by X-ray powder diffractometry, have characteristic X-ray diffraction peaks at least at diffraction angles of 7.1~, 19.8~, 17.3~ and 17.7~ (2.theta. CuK.alpha. , line). When the C-form crystals are …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 26, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 26, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 26, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.